Onkológia 5/2019
A comprehensive view of the treatment of metastatic hormone sensitive prostate cancer
Until the year 2015, androgen deprivation therapy (ADT) was the standard treatment of metastatic hormone sensitive prostate cancer (mHSPC). Since then, several clinical trials of patients with mHSPC have been reported to show a significant improvement in overall survival when ADT has been combined with docetaxel, abiraterone, apalutamide, enzalutamide and most recently with local prostate cancer radiotherapy. The present review provides the results of previous clinical trials phase 3 that gradually become the basis for a new standard of treatment for mHSPC.
Keywords: metastatic hormone sensitive prostate cancer, docetaxel, abiraterone, apalutamide, enzalutamide, radiotherapy
